<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911018-0063</DOCNO><DOCID>911018-0063.</DOCID><HL>   Somatix Therapy Acquisition</HL><DATE>10/18/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B6</SO><CO>   SOMA</CO><MS>TECHNOLOGY (TEC)</MS><IN>MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>CALIFORNIA (CA)NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   ALAMEDA, Calif. -- Somatix Therapy Corp. said it agreed toacquire privately held GeneSys Therapeutic Corp., La Jolla,Calif., for 3.6 million Somatix shares, currently valued at$26.1 million.   Both companies are engaged in developing gene therapy,disease treatments created by genetically modifying thebody's cells. The merged concern will concentrate inititallyon treatments for cancer, central nervous system diseases andcardiovascular diseases.</LP><TEXT>   The agreement is subject to approval by shareholders ofthe companies. GeneSys shareholders would own 29% ofSomatix's stock if the acquisition is completed.</TEXT></DOC>